These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 32318784)

  • 21. Optimization of Statistical Single Subject Analysis of Brain FDG PET for the Prognosis of Mild Cognitive Impairment-to-Alzheimer's Disease Conversion.
    Lange C; Suppa P; Frings L; Brenner W; Spies L; Buchert R
    J Alzheimers Dis; 2016; 49(4):945-959. PubMed ID: 26577523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic correlates of reserve and resilience in MCI due to Alzheimer's Disease (AD).
    Bauckneht M; Chincarini A; Piva R; Arnaldi D; Girtler N; Massa F; Pardini M; Grazzini M; Efeturk H; Pagani M; Sambuceti G; Nobili F; Morbelli S
    Alzheimers Res Ther; 2018 Apr; 10(1):35. PubMed ID: 29615111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progressive Disintegration of Brain Networking from Normal Aging to Alzheimer Disease: Analysis of Independent Components of
    Pagani M; Giuliani A; Öberg J; De Carli F; Morbelli S; Girtler N; Arnaldi D; Accardo J; Bauckneht M; Bongioanni F; Chincarini A; Sambuceti G; Jonsson C; Nobili F
    J Nucl Med; 2017 Jul; 58(7):1132-1139. PubMed ID: 28280223
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI.
    Ben Bouallègue F; Mariano-Goulart D; Payoux P;
    J Alzheimers Dis; 2018; 62(1):399-408. PubMed ID: 29439345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FDG-PET as an independent biomarker for Alzheimer's biological diagnosis: a longitudinal study.
    Ou YN; Xu W; Li JQ; Guo Y; Cui M; Chen KL; Huang YY; Dong Q; Tan L; Yu JT;
    Alzheimers Res Ther; 2019 Jun; 11(1):57. PubMed ID: 31253185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aberrant MEG multi-frequency phase temporal synchronization predicts conversion from mild cognitive impairment-to-Alzheimer's disease.
    Pusil S; Dimitriadis SI; López ME; Pereda E; Maestú F
    Neuroimage Clin; 2019; 24():101972. PubMed ID: 31522127
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The associations of serum valine with mild cognitive impairment and Alzheimer's disease.
    Xiong YL; Therriault J; Ren SJ; Jing XJ; Zhang H;
    Aging Clin Exp Res; 2022 Aug; 34(8):1807-1817. PubMed ID: 35362856
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Controls-based denoising, a new approach for medical image analysis, improves prediction of conversion to Alzheimer's disease with FDG-PET.
    Blum D; Liepelt-Scarfone I; Berg D; Gasser T; la Fougère C; Reimold M;
    Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2370-2379. PubMed ID: 31338550
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Principal Components Analysis of Brain Metabolism Predicts Development of Alzheimer Dementia.
    Blazhenets G; Ma Y; Sörensen A; Rücker G; Schiller F; Eidelberg D; Frings L; Meyer PT;
    J Nucl Med; 2019 Jun; 60(6):837-843. PubMed ID: 30389825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 18F-FDG PET for Prediction of Conversion to Alzheimer's Disease Dementia in People with Mild Cognitive Impairment: An Updated Systematic Review of Test Accuracy.
    Smailagic N; Lafortune L; Kelly S; Hyde C; Brayne C
    J Alzheimers Dis; 2018; 64(4):1175-1194. PubMed ID: 30010119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Individual Brain Metabolic Connectome Indicator Based on Jensen-Shannon Divergence Similarity Estimation Predicts Seizure Outcomes of Temporal Lobe Epilepsy.
    Zhu Z; Zhang Z; Gao X; Feng L; Chen D; Yang Z; Hu S
    Front Cell Dev Biol; 2021; 9():803800. PubMed ID: 35310541
    [No Abstract]   [Full Text] [Related]  

  • 32. Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia.
    Cerami C; Della Rosa PA; Magnani G; Santangelo R; Marcone A; Cappa SF; Perani D
    Neuroimage Clin; 2015; 7():187-94. PubMed ID: 25610780
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distinct subtypes of spatial brain metabolism patterns in Alzheimer's disease identified by deep learning-based FDG PET clusters.
    Ryoo HG; Choi H; Shi K; Rominger A; Lee DY; Lee DS;
    Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):443-454. PubMed ID: 37735259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A cross-sectional comparison of brain glucose and ketone metabolism in cognitively healthy older adults, mild cognitive impairment and early Alzheimer's disease.
    Croteau E; Castellano CA; Fortier M; Bocti C; Fulop T; Paquet N; Cunnane SC
    Exp Gerontol; 2018 Jul; 107():18-26. PubMed ID: 28709938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive Value of
    Blazhenets G; Ma Y; Sörensen A; Schiller F; Rücker G; Eidelberg D; Frings L; Meyer PT;
    J Nucl Med; 2020 Apr; 61(4):597-603. PubMed ID: 31628215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease.
    Leuzy A; Carter SF; Chiotis K; Almkvist O; Wall A; Nordberg A
    J Alzheimers Dis; 2015; 45(4):1077-88. PubMed ID: 25649653
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Cingulate Island Sign on FDG-PET vs. IMP-SPECT to Assess Mild Cognitive Impairment in Alzheimer's Disease vs. Dementia with Lewy Bodies.
    Chiba Y; Fujishiro H; Iseki E; Kasanuki K; Sato K
    J Neuroimaging; 2019 Nov; 29(6):712-720. PubMed ID: 31199036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Temporal and Spatial Analysis of Alzheimer's Disease Based on an Improved Convolutional Neural Network and a Resting-State FMRI Brain Functional Network.
    Sun H; Wang A; He S
    Int J Environ Res Public Health; 2022 Apr; 19(8):. PubMed ID: 35457373
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Learning Metabolic Brain Networks in MCI and AD by Robustness and Leave-One-Out Analysis: An FDG-PET Study.
    Yao Z; Hu B; Chen X; Xie Y; Gutknecht J; Majoe D
    Am J Alzheimers Dis Other Demen; 2018 Feb; 33(1):42-54. PubMed ID: 28931302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction.
    Hatashita S; Yamasaki H
    PLoS One; 2013; 8(6):e66877. PubMed ID: 23799136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.